{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:38:47Z","timestamp":1787233127741,"version":"build-2736575974"},"reference-count":56,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,1,6]],"date-time":"2015-01-06T00:00:00Z","timestamp":1420502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.ahj.2014.12.020","type":"journal-article","created":{"date-parts":[[2015,1,6]],"date-time":"2015-01-06T12:46:43Z","timestamp":1420548403000},"page":"464-471.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial\/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF)"],"prefix":"10.1016","volume":"169","clinical-trial-number":[{"clinical-trial-number":"nct01839357","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01928979","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Gregory Y.H.","family":"Lip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hammerstingl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Cappato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle Ling","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodo","family":"Kirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eolo","family":"Morandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"van Eickels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2014.12.020_bb0005","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/hrt.82.5.547","article-title":"Left atrial appendage: structure, function, and role in thromboembolism","volume":"82","author":"Al Saady","year":"1999","journal-title":"Heart"},{"key":"10.1016\/j.ahj.2014.12.020_bb0010","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/eurheartj\/eht499","article-title":"Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes","volume":"35","author":"Azoulay","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2014.12.020_bb0015","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1160\/TH13-07-0556","article-title":"Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation","volume":"110","author":"Gallego","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2014.12.020_bb0020","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1378\/chest.115.1.140","article-title":"Atrial thrombi resolution after prolonged anticoagulation in patients with atrial fibrillation","volume":"115","author":"Corrado","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2014.12.020_bb0025","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.110.977546","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion","volume":"123","author":"Nagarakanti","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.12.020_bb0030","doi-asserted-by":"crossref","first-page":"639","DOI":"10.7326\/0003-4819-128-8-199804150-00005","article-title":"Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography","volume":"128","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2014.12.020_bb0035","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/S0735-1097(02)01785-0","article-title":"Embolic events in patients with atrial fibrillation and effective anticoagulation: value of transesophageal echocardiography to guide direct-current cardioversion. Final results of the Ludwigshafen Observational Cardioversion Study","volume":"39","author":"Seidl","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.12.020_bb0040","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1161\/01.CIR.89.6.2509","article-title":"Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation. A multicenter study","volume":"89","author":"Black","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.12.020_bb0045","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ijcard.2006.03.036","article-title":"Role of transesophageal echocardiography guided cardioversion in patients with atrial fibrillation, previous left atrial thrombus and effective anticoagulation","volume":"113","author":"Saeed","year":"2006","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2014.12.020_bb0050","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0735-1097(00)01178-5","article-title":"Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation","volume":"37","author":"Klein","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.12.020_bb0055","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7326\/0003-4819-123-11-199512010-00001","article-title":"Accuracy of transesophageal echocardiography for identifying left atrial thrombi. A prospective, intraoperative study","volume":"123","author":"Manning","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2014.12.020_bb0060","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"Camm","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2014.12.020_bb0065","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1056\/NEJM200105103441901","article-title":"Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation","volume":"344","author":"Klein","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.12.020_bb0070","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijcard.2003.10.019","article-title":"Cardioversion under the guidance of transesophageal echochardiograhy in persistent atrial fibrillation: results with low molecular weight heparin","volume":"98","author":"Akdeniz","year":"2005","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2014.12.020_bb0075","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1161\/01.CIR.92.2.160","article-title":"Cardioversion of nonrheumatic atrial fibrillation. Reduced thromboembolic complications with 4 weeks of precardioversion anticoagulation are related to atrial thrombus resolution","volume":"92","author":"Collins","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.12.020_bb0080","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1067\/mhj.2000.106648","article-title":"Efficacy of anticoagulation in resolving left atrial and left atrial appendage thrombi: a transesophageal echocardiographic study","volume":"140","author":"Jaber","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2014.12.020_bb0085","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.jacc.2013.02.025","article-title":"Outcomes following cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial","volume":"61","author":"Piccini","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.12.020_bb0090","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2013.09.062","article-title":"Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation)","volume":"63","author":"Flaker","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.12.020_bb0095","first-page":"781","article-title":"Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel","volume":"111","author":"Husted","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2014.12.020_bb0100","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1160\/TH12-10-0772","article-title":"General mechanisms of coagulation and targets of anticoagulants (section I). Position paper of the ESC Working Group on Thrombosis\u2013Task Force on Anticoagulants in Heart Disease","volume":"109","author":"De Caterina","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2014.12.020_bb0105","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2014.12.020_bb0110","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s11239-012-0747-1","article-title":"Dabigatran and left atrial appendage thrombus","volume":"34","author":"Vidal","year":"2012","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.ahj.2014.12.020_bb0115","article-title":"Dabigratan has a higher risk of left atrial appendage thrombus formation in patients with AF when compared to warfarin and rivaroxaban","author":"Di Biase","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.12.020_bb0120","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1160\/TH12-11-0821","article-title":"Resolution of giant left atrial appendage thrombus with rivaroxaban","volume":"109","author":"Hammerstingl","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2014.12.020_bb0125","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000354315","article-title":"Dissolution of the left atrial appendage thrombus with rivaroxaban therapy","volume":"36","author":"Takasugi","year":"2013","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.ahj.2014.12.020_bb0130","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1477-9560-11-26","article-title":"Resolution of left atrial appendage thrombus with apixaban","volume":"11","author":"Kawakami","year":"2013","journal-title":"Thromb J"},{"key":"10.1016\/j.ahj.2014.12.020_bb0135","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-203870","article-title":"Use of apixaban for an elderly patient with left atrial thrombus","volume":"2014","author":"Dobashi","year":"2014","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.ahj.2014.12.020_bb0140","article-title":"Direct acting oral anticoagulants are more effective than vitamin-K-antagonists for the resolution of established left atrial thrombi in patients with atrial fibrillation","author":"Lambers","year":"2014","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.ahj.2014.12.020_bb0145","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1161\/ATVBAHA.110.202978","article-title":"Rivaroxaban: a new oral factor Xa inhibitor","volume":"30","author":"Perzborn","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2014.12.020_bb0150","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.jacc.2003.11.062","article-title":"Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation","volume":"43","author":"Conway","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.12.020_bb0155","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jacc.2012.11.046","article-title":"Effect of atrial fibrillation on atrial thrombogenesis in humans: impact of rate and rhythm","volume":"61","author":"Lim","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.12.020_bb0160","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/0735-1097(90)90589-H","article-title":"Increased intracardiovascular clotting in patients with chronic atrial fibrillation","volume":"16","author":"Kumagai","year":"1990","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.12.020_bb0165","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0195-668X(03)00239-2","article-title":"Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation","volume":"24","author":"Roldan","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2014.12.020_bb0170","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1136\/bmj.311.7020.1631","article-title":"ABC of atrial fibrillation. Drugs for atrial fibrillation","volume":"311","author":"Lip","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2014.12.020_bb0175","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1160\/TH03-06-0363","article-title":"High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy","volume":"90","author":"Vene","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2014.12.020_bb0180","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jjcc.2010.03.006","article-title":"Systemic inflammation and left atrial thrombus in patients with non-rheumatic atrial fibrillation","volume":"56","author":"Maehama","year":"2010","journal-title":"J Cardiol"},{"key":"10.1016\/j.ahj.2014.12.020_bb0185","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1161\/01.CIR.101.15.1767","article-title":"Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men","volume":"101","author":"Ridker","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.12.020_bb0190","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0140-6736(01)06112-8","article-title":"Role of inflammatory biomarkers in prediction of coronary heart disease","volume":"358","author":"Ridker","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2014.12.020_bb0195","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0002-8703(98)70149-8","article-title":"Hypofibrinolysis in atrial fibrillation","volume":"136","author":"Roldan","year":"1998","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2014.12.020_bb0200","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1161\/01.CIR.0000039327.11661.16","article-title":"Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke","volume":"106","author":"Cai","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.12.020_bb0205","first-page":"219","article-title":"Anticoagulant therapy modifies fibrinolytic dysfunction in chronic atrial fibrillation","volume":"30","author":"Roldan","year":"2000","journal-title":"Haemostasis"},{"key":"10.1016\/j.ahj.2014.12.020_bb0210","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000339426","article-title":"von Willebrand factor: more than a regulator of hemostasis and thrombosis","volume":"128","author":"Luo","year":"2012","journal-title":"Acta Haematol"},{"key":"10.1016\/j.ahj.2014.12.020_bb0215","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1016\/j.jacc.2010.12.033","article-title":"Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients","volume":"57","author":"Roldan","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.12.020_bb0220","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1161\/ATVBAHA.111.232991","article-title":"Left atrial blood stasis and von Willebrand factor-ADAMTS13 homeostasis in atrial fibrillation","volume":"31","author":"Ammash","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2014.12.020_bb0225","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1161\/01.STR.0000236840.00467.84","article-title":"Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation","volume":"37","author":"Lip","year":"2006","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2014.12.020_bb0230","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1161\/01.CIR.0000077912.12202.FC","article-title":"Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation","volume":"107","author":"Conway","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.12.020_bb0235","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/1074248413501392","article-title":"Novel oral anticoagulants in cardiovascular disease","volume":"19","author":"Gallego","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.ahj.2014.12.020_bb0240","first-page":"305","article-title":"A review of warfarin dosing and monitoring","volume":"14","author":"Kuruvilla","year":"2001","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"10.1016\/j.ahj.2014.12.020_bb0245","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1253\/circj.CJ-11-0304","article-title":"Antithrombotic therapy in atrial fibrillation: evaluation and positioning of new oral anticoagulant agents","volume":"75","author":"Ogawa","year":"2011","journal-title":"Circ J"},{"key":"10.1016\/j.ahj.2014.12.020_bb0250","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1538-7836.2007.02473.x","article-title":"Factor Xa or thrombin: is factor Xa a better target?","volume":"5","author":"Ansell","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2014.12.020_bb0255","doi-asserted-by":"crossref","DOI":"10.1096\/fasebj.26.1_supplement.832.7","article-title":"Effect of dabigatran and rivaroxaban on thrombomodulin mediated activation of protein C and thrombin activated fibrinolysis inhibitor (TAFI)","author":"Fareed","year":"2012","journal-title":"FASEB J"},{"key":"10.1016\/j.ahj.2014.12.020_bb0260","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1161\/01.ATV.0000193624.28251.83","article-title":"What does it take to make the perfect clot?","volume":"26","author":"Monroe","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2014.12.020_bb0265","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijcard.2003.10.019","article-title":"Cardioversion under the guidance of transesophageal echochardiography in persistent atrial fibrillation: results with low molecular weight heparin","volume":"98","author":"Akdeniz","year":"2005","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2014.12.020_bb0290","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jjcc.2011.06.009","article-title":"Left atrial thrombus and prognosis after anticoagulation therapy in patients with atrial fibrillation","volume":"58","author":"Fukuda","year":"2011","journal-title":"J Cardiol"},{"key":"10.1016\/j.ahj.2014.12.020_bb0325","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/0002-8703(91)90027-F","article-title":"Left atrial ball thrombus: review of clinical and echocardiographic manifestations with suggestions for management","volume":"121","author":"Wrisley","year":"1991","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2014.12.020_bb0330","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/oxfordjournals.eurheartj.a062560","article-title":"Left atrial ball thrombus: echocardiographic features and clinical implications","volume":"9","author":"Fraser","year":"1988","journal-title":"Eur Heart J"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870315000113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870315000113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:53:59Z","timestamp":1757570039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870315000113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0002870315000113"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2014.12.020","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial\/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF)","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2014.12.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Mosby, Inc.","name":"copyright","label":"Copyright"}]}}